Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Meningeal Carcinomatosis 2Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Medulloblastoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 6sonidegib 4Irinotecan 3Topotecan 2LY2940680 2Cyclophosphamide 2ribociclib 1pomalidomide 1palbociclib 1omburtamab I-131 1exatecan 1entrectinib 1dinutuximab 1bempegaldesleukin 1abemaciclib 1TB-403 1Pemetrexed 1ONC206 1Nivolumab 1NVP-LEQ506 1Granulocyte-Macrophage Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Etoposide 1CLR1404 1Biological Factors 190Y-octreotide, DOTA-Tyr(3)- 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Medulloblastoma × omburtamab I-131 × Clear all
NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Y-mAbs Therapeutics

Phase 1 Terminated
177 enrolled
CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡